Deals & Corporate Governance

  • August 12, 2025

    Bayer Bets $1.3B On Kumquat Cancer Drug Candidate

    Pharmaceutical company Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company, on Tuesday announced that they have entered into an exclusive global license and collaboration agreement under which Kumquat will receive up to $1.3 billion to help develop and commercialize its pancreatic cancer-focused drug candidate.

  • August 12, 2025

    FTC Skeptical Of 'Partial' Sale For GTCR Merger Fix

    The Federal Trade Commission told an Illinois federal court that enforcers are reviewing an offer by private equity firm GTCR BC Holding to sell parts of a medical device coatings company in order to fix concerns raised by the company's planned purchase of Surmodics, but said a full sale is preferable.

  • August 12, 2025

    Roche Settles Trade Secrets Suit With Stanford And Profs

    Subsidiaries of F. Hoffmann-La Roche AG have settled claims with a competing startup founded by Stanford University professors to resolve claims of trade secret theft related to cancer detection technology.

  • August 12, 2025

    3 Firms Advise As Cardinal Health Makes $1.9B Urology Push

    Cardinal Health said Tuesday that one of its specialty platforms has agreed to acquire a top urology company known as Solaris Health from Lee Equity Partners and Solaris' physician owners for $1.9 billion, in a deal steered by three law firms.

  • August 11, 2025

    GTCR Says Sale, Market Nix FTC Med Tech Merger Concerns

    Private equity firm GTCR BC Holdings urged an Illinois federal judge not to block its planned $627 million purchase of a medical device coatings company, arguing in a brief made public Friday that a planned divestiture fully resolves Federal Trade Commission concerns.

  • August 11, 2025

    Hospital Groups Back Challenge Of Merger Notice Overhaul

    A pair of hospital trade associations threw their support behind a U.S. Chamber of Commerce case challenging the Federal Trade Commission's new premerger filing requirements, telling a Texas federal court the agency was wrong to invoke the hospital industry when justifying the changes.

  • August 11, 2025

    DOJ Touts Merger, Rental Algorithm Deals, Eyeing More

    The head of the U.S. Department of Justice's Antitrust Division on Monday touted two recent settlements, in a merger case and in the RealPage algorithmic rent-fixing litigation, as indications that Trump administration enforcers will focus on algorithm-based price-fixing and are willing to "negotiate favorable settlements."

  • August 11, 2025

    Claims Court Judge Orders VA To Redo Drug Procurement

    The U.S. Court of Federal Claims has ruled that the Department of Veterans Affairs violated the Trade Agreements Act by opting to purchase prostate medication from a company sourcing the drug from India, a non-TAA designation country.

  • August 11, 2025

    Greystone Issues $64.9M Loan For Penn. Healthcare Portfolio

    Greystone has provided a nonrecourse, 24-month bridge loan of more than $64.9 million for a 506-bed, three-property Pennsylvania healthcare portfolio, the commercial real estate finance company announced Monday.

  • August 07, 2025

    Fed. Circ. Affirms PTAB Ax Of Bone Fusion Device Patents

    The Federal Circuit on Thursday upheld Patent Trial and Appeal Board rulings that invalidated claims in a pair of Stryker Corp. patents for a surgical implant that a Berkshire Hathaway-owned rival had challenged.

  • August 07, 2025

    UnitedHealth Selling Home Health Branches In DOJ Deal

    The U.S. Department of Justice announced a settlement Thursday resolving its Maryland federal court challenge to UnitedHealth's $3.3 billion acquisition of home health and hospice company Amedisys, with the deal requiring the companies to sell at least 164 locations across 19 states.

  • August 06, 2025

    Ga. Judges Weigh Birth Defect Ruling in Sterigenics Case

    A group of Georgia residents who alleged they were injured by emissions from a Sterigenics sterilization plant urged the Georgia Court of Appeals on Wednesday to overturn a lower court's grant of partial summary judgment to the company on the issue of whether the plant's emissions caused birth defects.

  • August 05, 2025

    Novo Nordisk Lodges Suits Over 'Knockoff' Semaglutide Meds

    Novo Nordisk said Tuesday it has recently filed more than a dozen lawsuits accusing weight loss companies, med spas and pharmacies of tricking patients into purchasing and using unapproved drugs containing semaglutide, which the Danish pharmaceutical company uses in its blockbuster medicines Wegovy and Ozempic.

  • August 05, 2025

    Stewart Won't Reconsider Her 1st Settled Expectations Denial

    The acting U.S. Patent and Trademark Office director on Tuesday stood by her first-ever decision that an older patent shouldn't have to face Patent Trial and Appeal Board scrutiny.

  • August 05, 2025

    Gibson Dunn, Wachtell Advise On $1.5B Vision Implant Deal

    Global eye care company Alcon announced Tuesday that it has agreed to acquire STAAR Surgical Co. for approximately $1.5 billion in cash, aiming to broaden its portfolio in the growing surgical vision correction market.

  • August 04, 2025

    GTCR Says Buyer In Place For Potential FTC Divestiture Deal

    Private equity firm GTCR BC Holdings told an Illinois federal court it has a signed agreement with a buyer for a deal that should fix the concerns raised by the Federal Trade Commission over its planned $627 million purchase of a medical device coatings company.

  • August 04, 2025

    Investors Say Novo Nordisk Misled Them Over Drug Demand

    Novo Nordisk was hit with a proposed securities class action in New Jersey federal court alleging the company misled investors over its revenue outlook for 2025 by allegedly overstating the likelihood patients would switch to its branded diabetes and weight loss drugs.

  • July 31, 2025

    Biotech Co. Beats Investor Suit Over Antifungal Drug Recall

    Biotechnology company Scynexis Inc. has won dismissal, for now, of a proposed investor class action alleging that it triggered a 34% share decline by knowingly misleading investors about manufacturing compliance issues that led to a drug recall, with the court finding the allegations the company should have known and disclosed issues only show "fraud by hindsight."

  • July 30, 2025

    ImmunityBio Investors Nab Initial OK On Derivative Suit Deal

    A California federal judge has granted initial approval to a deal ending derivative claims that ImmunityBio executives failed to disclose manufacturing deficiencies that doomed the company's lead cancer drug application.

  • July 29, 2025

    Ocugen Beats Investor Suit Over Financial Controls

    Biopharmaceutical company Ocugen Inc. on Tuesday won permanent dismissal from an investor's class action accusing it of concealing weak financial controls that led to it refiling accounting statements for several periods, with a Pennsylvania federal judge determining that Ocugen's stock price recovered from the announcement it had erred in its reports.

  • July 29, 2025

    This Week's Healthcare Earnings: UnitedHealth, AstraZeneca

    A host of companies posted their second-quarter financial results this past week, offering a look into how health systems, payors and pharmaceutical companies fared over the past few months.

  • July 29, 2025

    Pharma Co. Blasts Adversary For Nudging Judge Assignment

    A pharmaceutical solutions group has assailed its opponent's "hurry-up-court" motion nudging the appointment of a new judge after the previous judge overseeing their contract fight retired, saying its adversary "has only itself to blame" for the alleged delays that have put off a final resolution.

  • July 28, 2025

    Arnold & Porter Opens Seattle Office With K&L Gates Attys

    Arnold & Porter Kaye Scholer LLP announced Monday that it has opened a Seattle office with three former K&L Gates LLP partners, and added a fourth attorney from that firm in New Jersey.

  • July 25, 2025

    Hospital Giant To Pay $3.5M Over Nurse Training Repayments

    HCA Healthcare Inc., a major U.S. hospital operator, has agreed to pay roughly $3.5 million to settle claims that it unlawfully trapped new nurses in agreements requiring them to repay training costs if they left their jobs within two years, according to a trio of state attorneys general.

  • July 24, 2025

    Medical Device Firm GC's Pay Soars After $202M IPO

    The general counsel for medical device company Kestra Medical Technologies Inc., which priced a $202 million initial public offering in March, saw her total compensation soar from just under $500,000 during the 2024 fiscal year to more than $6 million in 2025.

Expert Analysis

  • Virginia 'Rocket Docket' Slowdown Is Likely A Blip

    Author Photo

    After being the fastest or second-fastest federal civil trial court for 14 straight years, the Eastern District of Virginia has slid to 18th place, but the rocket docket’s statistical tumble doesn't mean the district no longer maintains a speedy civil docket, says Robert Tata at Hunton.

  • A Look At 2023's Major NLRB Developments Thus Far

    Author Photo

    Over the last six months, the National Labor Relations Board has broadened its interpretation and enforcement of the National Labor Relations Act, including increasing penalties and efforts to prohibit restrictive covenants and confidentiality agreements, say Eve Klein and Elizabeth Mincer at Duane Morris.

  • Preparing For Md. Adult-Use Cannabis: Licensing Provisions

    Author Photo

    As the launch of Maryland’s adult-use cannabis market quickly approaches, current and prospective businesses will need to understand key provisions and limitations related to license conversion, qualifying partnerships, social equity applications and microlicenses, say Seth Gitner and Jonathan Havens at Saul Ewing.

  • FTC's Amgen-Horizon Protest Raises Conglomerate Concerns

    Author Photo

    The Federal Trade Commission's challenge to Amgen Inc.'s proposed $28 billion acquisition of Horizon Therapeutics is the agency's first move in four decades based on a conglomerate theory of competitive harm, and might pose new antitrust risks for transactions beyond the pharmaceutical sector, say attorneys at WilmerHale.

  • 5 Management Tips To Keep Law Firm Merger Talks Moving

    Author Photo

    Many law firm mergers that make solid business sense still fall apart due to the costs and frustrations of inefficient negotiations, but firm managers can increase the chance of success by effectively planning and executing merger discussions, say Lisa Smith and Kristin Stark at Fairfax Associates.

  • What 3rd Circ. Niaspan Decision Means For Class Cert.

    Author Photo

    The Third Circuit's recent denial of class certification in the Niaspan antitrust case underscores its particularly stringent understanding of the implicit ascertainability requirement, which further fuels confusion in the courts, threatens uneven results and increases the risk of forum shopping, says Michael Lazaroff at Rimon Law.

  • The Texas Two-Step May Be Losing Steam

    Author Photo

    The Texas Two-Step is a powerful bankruptcy strategy that has been used in recent high-profile cases, including Johnson & Johnson’s talc unit bankruptcy case, but ongoing debate and legal challenges raise the question of whether this maneuver is losing reliability, say Brendan Best and Justin Allen at Varnum.

  • FTC Pharma Merger Digest May Offer Policy Clues

    Author Photo

    The Federal Trade Commission's and the U.S. Justice Department's recently published summary of the agencies' workshop on proposed changes to pharmaceutical merger analysis reads like a policy roadmap and its timing may forecast the release of new draft merger guidelines, say attorneys at Mintz.

  • Rethinking In-Office Attendance For Associate Retention

    Author Photo

    The hybrid office attendance model doesn't work for all employees, but it does for many — and balancing these two groups is important for associate retention and maintaining a BigLaw firm culture that supports all attorneys, says Summer Eberhard at Major Lindsey.

  • Avoiding Antitrust Enforcement In Health Care Joint Ventures

    Author Photo

    Considering the Federal Trade Commission's recent activity in challenging hospital combinations, health care companies must be mindful of antitrust considerations unique to the industry, and employ strategies to minimize enforcement risks, say attorneys at Holland & Knight.

  • Murdaugh Trials Offer Law Firms Fraud Prevention Reminders

    Author Photo

    As the fraud case against Alex Murdaugh continues to play out, the evidence and narrative presented at his murder trial earlier this year may provide lessons for law firms on implementing robust internal controls that can detect and prevent similar kinds of fraud, say Travis Casner and Helga Zauner at Weaver and Tidwell.

  • Check Onboarding Docs To Protect Arbitration Agreements

    Author Photo

    The California Court of Appeal's recent Alberto v. Cambrian Homecare decision opens a new and unexpected avenue of attack on employment arbitration agreements in California — using other employment-related agreements to render otherwise enforceable arbitration agreements unenforceable, say Morgan Forsey and Ian Michalak at Sheppard Mullin.

  • Firm Tips For Helping New Lawyers Succeed Post-Pandemic

    Author Photo

    Ten steps can help firms significantly enhance the experience of attorneys who started their careers in the coronavirus pandemic era, including facilitating opportunities for cross-firm connection, which can ultimately help build momentum for business development, says Lana Manganiello at Equinox Strategy Partners.